Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Robertson

Showing results (91-100 of 103) with videos related to

Pageof 11
Sort By:
Hepatology (Baltimore, Md.)|October 23, 2016
Short-duration treatment with elbasvir/grazoprevir and sofosbuvir for hepatitis C: A randomized trialEric Lawitz, Fred Poordad, Julio A Gutierrez, et al.
Plos One|September 15, 2015
Continued Follow-Up of Phambili Phase 2b Randomized HIV-1 Vaccine Trial Participants Supports Increased HIV-1 Acquisition among Vaccinated MenZoe Moodie, Barbara Metch, Linda-Gail Bekker, et al.
The Lancet. Infectious Diseases|February 25, 2014
Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili studyGlenda E Gray, Zoe Moodie, Barbara Metch, et al.
Hepatology (Baltimore, Md.)|March 4, 2017
Elbasvir/Grazoprevir for Patients With Hepatitis C Virus Infection and Inherited Blood Disorders: A Phase III StudyChristophe Hézode, Massimo Colombo, Marc Bourlière, et al.
Gastroenterology|October 11, 2016
Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C InfectionPaul Kwo, Edward J Gane, Cheng-Yuan Peng, et al.
Lancet (London, England)|October 13, 2015
Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 studyDavid Roth, David R Nelson, Annette Bruchfeld, et al.
Lancet (London, England)|December 4, 2014
Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trialEric Lawitz, Edward Gane, Brian Pearlman, et al.
Hepatology (Baltimore, Md.)|July 9, 2017
Grazoprevir, ruzasvir, and uprifosbuvir for hepatitis C virus after NS5A treatment failureDavid Wyles, Heiner Wedemeyer, Ziv Ben-Ari, et al.
AIDS Research and Human Retroviruses|January 29, 2013
Safety, tolerability, and efficacy of raltegravir in a diverse cohort of HIV-infected patients: 48-week results from the REALMRK StudyKathleen E Squires, Linda-Gail Bekker, Joseph J Eron, et al.
Lancet (London, England)|December 4, 2014
Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trialMark Sulkowski, Christophe Hezode, Jan Gerstoft, et al.
Pageof 11

Showing results (91-100 of 103) with videos related to

Sort By:
Pageof 11
Hepatology (Baltimore, Md.)|October 23, 2016
Short-duration treatment with elbasvir/grazoprevir and sofosbuvir for hepatitis C: A randomized trialEric Lawitz, Fred Poordad, Julio A Gutierrez, et al.
Plos One|September 15, 2015
Continued Follow-Up of Phambili Phase 2b Randomized HIV-1 Vaccine Trial Participants Supports Increased HIV-1 Acquisition among Vaccinated MenZoe Moodie, Barbara Metch, Linda-Gail Bekker, et al.
The Lancet. Infectious Diseases|February 25, 2014
Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili studyGlenda E Gray, Zoe Moodie, Barbara Metch, et al.
Hepatology (Baltimore, Md.)|March 4, 2017
Elbasvir/Grazoprevir for Patients With Hepatitis C Virus Infection and Inherited Blood Disorders: A Phase III StudyChristophe Hézode, Massimo Colombo, Marc Bourlière, et al.
Gastroenterology|October 11, 2016
Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C InfectionPaul Kwo, Edward J Gane, Cheng-Yuan Peng, et al.
Lancet (London, England)|October 13, 2015
Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 studyDavid Roth, David R Nelson, Annette Bruchfeld, et al.
Lancet (London, England)|December 4, 2014
Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trialEric Lawitz, Edward Gane, Brian Pearlman, et al.
Hepatology (Baltimore, Md.)|July 9, 2017
Grazoprevir, ruzasvir, and uprifosbuvir for hepatitis C virus after NS5A treatment failureDavid Wyles, Heiner Wedemeyer, Ziv Ben-Ari, et al.
AIDS Research and Human Retroviruses|January 29, 2013
Safety, tolerability, and efficacy of raltegravir in a diverse cohort of HIV-infected patients: 48-week results from the REALMRK StudyKathleen E Squires, Linda-Gail Bekker, Joseph J Eron, et al.
Lancet (London, England)|December 4, 2014
Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trialMark Sulkowski, Christophe Hezode, Jan Gerstoft, et al.
Pageof 11